Have a feature idea you'd love to see implemented?
Let us know!
EBS Emergent BioSolutions Inc
Price (delayed)
$8.1
Market cap
$438.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.93
Enterprise value
$945.09M
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated
Highlights
EBS's quick ratio has soared by 181% QoQ and by 163% YoY
EBS's EPS has soared by 74% year-on-year and by 65% since the previous quarter
EBS's equity is up by 32% since the previous quarter but it is down by 27% year-on-year
Key stats
What are the main financial stats of EBS
Market
Valuations
Earnings
Shares outstanding
54.18M
Market cap
$438.89M
Enterprise value
$945.09M
Price to book (P/B)
0.84
Price to sales (P/S)
0.38
EV/EBIT
N/A
EV/EBITDA
46.1
EV/Sales
0.84
Revenue
$1.13B
Gross profit
$377.1M
Net income
-$208.8M
EBIT
-$91.9M
EBITDA
$20.5M
Free cash flow
$145.7M
Per share
Balance sheet
Liquidity
EPS
-$3.93
EPS diluted
-$4.03
Free cash flow per share
$2.74
Book value per share
$9.61
Revenue per share
$21.2
TBVPS
$18.08
Total assets
$1.48B
Total liabilities
$969.4M
Debt
$662.6M
Equity
$508.4M
Working capital
$431.5M
Debt to equity
1.3
Current ratio
2.88
Quick ratio
1.21
Net debt/EBITDA
24.69
Margins
Efficiency
Dividend
EBITDA margin
1.8%
Gross margin
33.5%
Net margin
-18.6%
Operating margin
-12.7%
Return on assets
-12.6%
Return on equity
-37.8%
Return on invested capital
-7.1%
Return on capital employed
-7.4%
Return on sales
-8.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EBS stock price
How has the Emergent BioSolutions stock price performed over time
Intraday
0.5%
1 week
-4.48%
1 month
-8.78%
1 year
263.23%
YTD
237.5%
QTD
-2.99%
Financial performance
How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.13B
Gross profit
$377.1M
Operating income
-$143M
Net income
-$208.8M
Gross margin
33.5%
Net margin
-18.6%
EBS's operating income has soared by 81% YoY and by 68% from the previous quarter
The company's operating margin has surged by 81% YoY and by 69% QoQ
Emergent BioSolutions's net margin has surged by 74% YoY and by 65% QoQ
The net income has soared by 73% YoY and by 64% from the previous quarter
Growth
What is Emergent BioSolutions's growth rate over time
Valuation
What is Emergent BioSolutions stock price valuation
P/E
N/A
P/B
0.84
P/S
0.38
EV/EBIT
N/A
EV/EBITDA
46.1
EV/Sales
0.84
EBS's EPS has soared by 74% year-on-year and by 65% since the previous quarter
The price to book (P/B) is 68% higher than the last 4 quarters average of 0.5 but 48% lower than the 5-year quarterly average of 1.6
EBS's equity is up by 32% since the previous quarter but it is down by 27% year-on-year
The P/S is 90% above the last 4 quarters average of 0.2 but 73% below the 5-year quarterly average of 1.4
The company's revenue rose by 2.1% QoQ and by 2% YoY
Efficiency
How efficient is Emergent BioSolutions business performance
EBS's ROS has soared by 86% year-on-year and by 81% since the previous quarter
EBS's ROIC has soared by 82% YoY and by 80% QoQ
The company's return on assets has surged by 62% QoQ and by 59% YoY
EBS's return on equity has surged by 61% since the previous quarter and by 48% year-on-year
Dividends
What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EBS.
Financial health
How did Emergent BioSolutions financials performed over time
The total assets is 52% more than the total liabilities
EBS's quick ratio has soared by 181% QoQ and by 163% YoY
Emergent BioSolutions's current ratio has soared by 172% from the previous quarter and by 164% YoY
Emergent BioSolutions's debt is 30% higher than its equity
The debt to equity has decreased by 42% QoQ but it has increased by 4.8% YoY
EBS's equity is up by 32% since the previous quarter but it is down by 27% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.